Mobile Site ›

PSA Standardization


Slide 34

October 2009

In conclusion, PSA assays remain problematic due to a lack of true standardization between WHO calibrated assays, which are needed for screening and diagnostic tests.  If a lab changes from a Hybritech assay to a WHO standardized assay, use of different cutoffs should be utilized and education of physicians about the change is critical.  Furthermore, many new biomarkers are on the horizon for earlier detection and prediction of prostate cancer.  There are many clinical decisions made off of PSA measurements, and there will continue to be until we can give clinicians something that is superior to PSA.



Jump to section: